Erasca, Inc.
NASDAQ:ERASBiotechnology
-$0.02 today
- Market cap
- $4.83B
- Beta
- 0.73
- P/E (TTM)
- -15.3
- EPS (TTM)
- -$0.91
Volume 8.94M
Average 6.79M
ERAS Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Erasca, Inc.NASDAQ: ERAS
Capital Expenditures · Q3 FY2026 · quarter ended Sep 2026
Capital expenditures growth accelerates
Q3 FY2026 capital expenditures of $79K (cash outflow) rose 1216.7% year over year, ahead of the +10.9% change in trailing-twelve-month capital expenditures. Sequentially, it rose 887.5% from the prior quarter. Over 3 fiscal years it compounded at -80.2% a year.
Context
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +1216.7% holds above the trailing-twelve-month pace of +10.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (128K) USD
- Year-over-year change
- +99.4%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (128K) | +99.4% |
| FY2024 | 2024-12-31 | (22.56M) | -1171.0% |
| FY2023 | 2023-12-31 | (1.78M) | +89.3% |
| FY2022 | 2022-12-31 | (16.55M) | +12.4% |
| FY2021 | 2021-12-31 | (18.89M) | — |
Capital Expenditures vs competitors
How ERAS compares with its peers on the latest reported figures
- ERAS's LTM Sep 2026 capital expenditures of $132K is the 7th largest of the 9 companies compared; the peer median is $916K.
- Its year-over-year change of +10.9% is the 3rd highest of 8, against a peer median of -48.1%.
- Over three fiscal years its annual growth of -80.2% compares with a peer median of -6.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $9.1M | -41.1% | +13.9% | — | |
| LTM Mar 2026 | $6.47M | +852.1% | +119.7% | 9.0% | |
| LTM Mar 2026 | $2.01M | -48.1% | -11.7% | 0.9% | |
| LTM Mar 2026 | $1.35M | +19114.3% | — | 2.7% | |
| LTM Mar 2026 | $487K | -64.1% | -30.0% | — | |
| LTM Sep 2026 | $299K | -68.5% | -48.5% | — | |
| LTM Sep 2026 | $132K | +10.9% | -80.2% | — | |
| LTM Jun 2026 | $101K | -74.0% | -1.5% | 0.1% | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding ERAS) | $916K | -48.1% | -6.6% | 1.8% | |
Competitors are the stored peer set for ERAS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (122.76M) | (242.81M) | (125.04M) | (161.65M) | (124.55M) |
| Depreciation & Amortization | 829K | 2.64M | 3.73M | 3.81M | 3.11M |
| Deferred Income Tax | (1.51M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.33M | 20.11M | 26.23M | 26.97M | 24.9M |
| Change in Working Capital | 7.71M | 15.79M | 813K | 1.74M | (3.33M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.34M | 676K | (886K) | (1.53M) | 513K |
| Other Working Capital | 6.36M | 15.11M | 1.7M | 3.27M | (3.84M) |
| Other Non-Cash Items | 27.81M | 101.01M | (6.95M) | 19.72M | 4.41M |
| Operating Cash Flow | (79.6M) | (103.26M) | (101.22M) | (109.42M) | (95.46M) |
| Capital Expenditures | (18.89M) | (16.55M) | (1.78M) | (22.56M) | (128K) |
| Acquisitions (Net) | 7.68M | 4M | 0 | 0 | 0 |
| Purchases of Investments | (105.82M) | (134.33M) | (314.39M) | (403.38M) | (150.97M) |
| Sales of Investments | 60.11M | 79.8M | 244.95M | 269.33M | 261.03M |
| Other Investing Activities | (7.68M) | (4M) | (20M) | (22.5M) | (9.5M) |
| Investing Cash Flow | (64.59M) | (71.08M) | (91.22M) | (156.62M) | 100.43M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 317M | 95.25M | 1.3M | 239.06M | 1.1M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.01M | 2.82M | 0 | 1.64M | 0 |
| Financing Cash Flow | 439.4M | 98.08M | 1.3M | 240.7M | 1.1M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 295.21M | (76.27M) | (191.14M) | (25.34M) | 6.07M |
| Free Cash Flow | (98.49M) | (119.82M) | (102.99M) | (131.98M) | (95.58M) |
Erasca, Inc.
NASDAQ:ERAS
Intrinsic Alpha fair value
Locked
Current Price
$13.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.